DLG4 Human Pre-designed siRNA Set A

Cat. No.: D1479935

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Vue d’ensemble

DLG4 Human Pre-designed siRNA Set A contains three designed siRNAs for DLG4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DLG4 siRNA-1: 5 nmol (HPLC) DLG4 siRNA-2: 5 nmol (HPLC) DLG4 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Conditions de stockage de stockage

Store at -20°C

Expédié en

Ice chest + Ice pads

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Product Line

Produits biologiques

Application Protocols

No tested applications, recommended dilutions, or step-by-step protocols are provided in the Product Data for this item.

Please refer to the product’s CoA/Spec Sheet for any available guidance and follow the instructions of your chosen transfection reagent. For research use only.

Biological Roles

Target gene context (literature; not item-specific claims):

• DLG4 (PSD-95) encodes a membrane-associated guanylate kinase (MAGUK) scaffolding protein that localizes to the postsynaptic density (PSD) of excitatory synapses.
• Structural role: Organizes NMDA and AMPA receptor complexes and links them to signaling enzymes and cytoskeletal elements via PDZ, SH3, and GK domains.
• Functional role: Modulates synaptic strength, receptor trafficking, and synapse maturation; implicated in synaptic plasticity phenomena such as LTP/LTD in neuronal systems.
• Interactions: Binds NR2 subunits of NMDA receptors, stargazin/TARPs associated with AMPA receptors, neuroligins, potassium channels, and nitric oxide synthase adapters (e.g., nNOS via PSD-95–NOS interactions) in various model systems.
• Cellular pathways: Coordinates glutamatergic signaling, calcium-dependent cascades, and downstream kinase pathways that shape dendritic spine morphology and synaptic efficacy.

Use of this siRNA set enables research interrogation of these roles by transiently reducing DLG4 expression to dissect pathway dependencies, validate molecular interactions, and benchmark phenotypes in cellular models. All uses are for research only; no diagnostic or clinical use is implied.

Buffer Applications

This product is not a buffering agent. However, buffers are central to its handling and use in RNAi workflows.

General buffer guidance for siRNA handling (literature; item-specific instructions are not provided):

• Reconstitution: Nuclease-free water or low-EDTA TE buffer (10 mM Tris, 0.1–1 mM EDTA, pH 7.5–8.0) are commonly used to enhance stability via chelation of divalent cations.
• Working dilutions: Prepare in RNase-free PBS or Opti-MEM/serum-reduced media as recommended by the transfection reagent manufacturer; avoid Mg2+/Ca2+ during storage.
• pH range: Near-neutral pH (7.0–8.0) is typical for stability and cell compatibility.
• Filtration: Use sterile, RNase-free 0.22 µm filtration only if needed and if validated not to cause adsorption losses.

No item-specific buffer recipes or concentrations are provided in the Product Data. Refer to the CoA/Spec Sheet and to your transfection reagent documentation for buffer compatibility and complex formation conditions.

Green Alternatives

While siRNA use itself is relatively benign compared to many small-molecule processes, sustainability opportunities focus on ancillary reagents, plastic use, and waste minimization.

Greener practice considerations (general):

• Buffer selection: Prefer aqueous, nuclease-free buffers (water or TE) over formulations requiring organic co-solvents. Avoid DEPC-treated water handling hazards by using certified nuclease-free water.
• Transfection reagents: Evaluate lower-toxicity, serum-compatible formulations that reduce cell washing steps and buffer exchanges, thereby decreasing consumables and waste.
• Plastic reduction: Use multiwell formats and miniaturized assays to reduce tube/tip consumption; adopt reusable RNase-free racks and reservoirs where feasible.
• Shipping/storage: Coordinate consolidated shipments to reduce cold-chain packaging waste; store at recommended temperatures to avoid product loss and re-orders.
• Waste management: Segregate nucleic acid-containing waste and decontaminate with less hazardous agents where validated (e.g., enzymatic RNase deactivation vs harsh chemicals), consistent with institutional policies.

Comparison (general):

• Conventional workflow: Higher plastic and reagent consumption; potential organic solvent use for certain delivery methods.
• Streamlined workflow: Aqueous-only buffers, serum-compatible transfections, reduced washing steps—lower waste and energy.

Item-specific green certifications or alternative SKUs are not specified for this product.

Pharmaceutical Uses

No pharmaceutical/formulation uses are specified for this product. This is a research-use-only siRNA set intended for laboratory studies such as gene knockdown in cell culture models.

Context (general, non-clinical):

• siRNAs can serve as discovery tools in target validation, mechanism-of-action studies, and lead identification workflows within preclinical research settings.
• This SKU is not manufactured or designated for diagnostic, therapeutic, or GMP applications, and no pharmacopeial status is indicated.

For any regulated or translational work, consult appropriate GMP-qualified materials and documentation. Item-specific excipient roles, formulation grades, or compliance standards are not specified for this product.

Physical Properties

Item-specific physicochemical parameters for this siRNA set are not provided in the Product Data. The following notes distinguish non-specified values from general literature expectations for siRNA duplexes.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet. (Literature: a 21-mer RNA duplex typically ~13–14 kDa per duplex, sequence-dependent.)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet. (Literature: readily soluble in nuclease-free water and low-salt buffers.)
• pKa / logP: Not applicable in the conventional small-molecule sense; siRNAs are highly polyanionic biopolymers (literature).
• UV characteristics (literature): Strong absorbance at 260 nm; A260 of 1.0 typically ~40 µg/mL for single-stranded RNA, sequence and duplex state dependent. Item-specific extinction coefficients are not specified.
• Melting temperature (Tm): Not specified for this item; refer to CoA/Spec Sheet. (Literature: Tm increases with GC content, length, and salt; typical siRNA Tm values often >60 °C in standard buffers.)
• Formulation: Not specified for this item; refer to CoA/Spec Sheet (e.g., salt form, lyophilized vs solution).

Use the Certificate of Analysis for definitive values pertinent to this exact set. When preparing solutions, employ RNase-free water/buffers and determine concentration by A260 only if the extinction coefficient is provided for the specific sequences.

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

Interpretation and context for siRNA quality (general guidance):

• Purification level: siRNAs may be provided as desalting-only, cartridge-purified, PAGE-purified, or HPLC-purified. Higher-purity preparations reduce truncated species and enhance reproducibility in transfection experiments. The specific purification for this item is not specified.
• Identity confirmation: Typical methods include MALDI-TOF/ESI-MS and analytical HPLC or ion-exchange profiles (literature). Item-specific certificates should be consulted for exact methods used.
• Quantitation: Delivered amount may be reported in nmol or OD260 units. Extinction coefficients and A260 conversions are sequence-specific; not specified here.
• Endotoxin and bioburden: For cell-based assays, low endotoxin is preferred. Any endotoxin/bioburden controls are not specified for this item.
• Stabilizers/lyoprotectants: Some siRNAs ship with volatile buffers or lyoprotectants (e.g., small amounts of Na+ salts). None are specified for this item.

What the grade means for use:

• If HPLC/PAGE-purified (if indicated on CoA), expect tighter duplex integrity and more consistent knockdown.
• If research-grade without cell therapy claims, this product is intended for in vitro research use in cell lines or primary cells, not for diagnostic or clinical applications.

Always verify the accompanying CoA/Spec Sheet for the exact specifications of SKU D1479935.

Reaction and Applications

As a pre-designed siRNA set targeting human DLG4, this reagent is intended for RNA interference (RNAi) experiments in mammalian cells to transiently suppress DLG4 mRNA levels.

Typical research applications (general; expand on manufacturer’s intent):

• Target knockdown: Reduce DLG4 (PSD-95) transcript and protein levels to interrogate postsynaptic scaffolding functions, receptor clustering, and downstream signaling pathways in neuronal or model cell systems.
• Pathway analysis: Dissect NMDA/AMPA receptor-associated signaling complexes influenced by DLG4 scaffolding; quantify impact via qRT-PCR, immunoblotting, or immunocytochemistry.
• Phenotypic screens: Employ the set (multiple independent siRNAs) to mitigate off-target confounders; concordant phenotypes across distinct duplexes strengthen on-target attribution.
• Rescue experiments: Combine knockdown with siRNA-resistant DLG4 cDNA expression to validate specificity (literature best practice).
• Combinatorial perturbation: Pair with siRNAs against interacting MAGUKs or receptors to map functional redundancy and network effects.

Practical tips (general):

• Use RNase-free technique throughout.
• Optimize transfection conditions (cell density, reagent type, siRNA dose, and exposure time). Typical working ranges are 1–50 nM siRNA in culture (literature), but item-specific instructions are not provided.
• Include controls: non-targeting siRNA, positive control siRNA (e.g., against a housekeeping gene), and mock transfection.

Note: No item-specific protocol or performance claims are provided; validate in your system and consult the CoA/Spec Sheet for any available guidance.

Reaction Conditions

Chemical reaction conditions are not applicable. For siRNA-mediated knockdown, practical transfection and incubation parameters are the relevant “conditions.” Item-specific protocols are not provided in the Product Data; consult your transfection reagent documentation. The following are literature-based considerations to aid experimental design:

• Cell density: Seed to achieve 50–70% confluence at transfection to balance uptake and viability.
• Dose range: 1–50 nM siRNA final concentration is commonly screened; optimize to minimize off-target effects while achieving knockdown.
• Complexation: Prepare siRNA–reagent complexes in serum-free medium per reagent instructions; incubate 10–30 min before addition to cells.
• Incubation: 4–6 h exposure in serum-free conditions followed by media change, or serum-compatible protocols if supported by the reagent.
• Assessment timeline: mRNA reduction often evident by 24–48 h; protein knockdown may require 48–96 h depending on turnover.
• Controls: Non-targeting siRNA, on-target positive control, and mock transfection; consider dose–response.
• Readouts: qRT-PCR for transcript; immunoblot/ELISA/imaging for protein. Normalize to housekeeping genes/proteins.

These parameters are general guidance only. Validate conditions for your cell type and endpoint. Adhere to aseptic, RNase-free technique throughout.

Safety and Handling

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / Pictograms: Not specified for this item; refer to SDS.
• For research use only.

Practical handling guidance (general for siRNA/oligonucleotides; always defer to SDS):

• Work using RNase-free technique to prevent degradation: wear gloves, use RNase-free tubes and barrier tips, and avoid touching tube rims/tips.
• Personal protective equipment: lab coat, safety glasses, and appropriate gloves. Avoid inhalation of powders/aerosols and contact with skin/eyes.
• Engineering controls: handle lyophilized materials and solutions in a clean area; consider a clean bench to minimize nuclease contamination.
• Incompatibilities (general): Avoid strong acids/bases and nucleases. Divalent cations and high temperatures can accelerate hydrolysis of RNA (literature).
• First aid (general):
  • Skin/eye contact: rinse with water for several minutes; remove contaminated clothing; seek medical attention if irritation persists.
  • Inhalation/ingestion: move to fresh air; rinse mouth with water; seek medical attention as appropriate.
• Spill/cleanup: For powders, avoid dust formation; gently wipe with damp RNase-free wipes. For solutions, absorb with disposable towels; decontaminate surfaces with RNase deactivation agents or 70% ethanol, as appropriate.
• Waste: Dispose of according to institutional and local regulations for laboratory biological/chemical waste.

Always consult the product-specific SDS for authoritative hazard and handling information.

Solvent Selection

This product is an siRNA set; the relevant “solvent” context is reconstitution and dilution media for oligonucleotides rather than organic solvent screening.

• Applicable media (general/literature):
  • Nuclease-free water: Common for initial reconstitution when immediate use is planned.
  • TE buffer (10 mM Tris, 0.1–1 mM EDTA, pH 7.5–8.0): Helps chelate divalent cations and can improve long-term stability (literature). Item-specific recommendations are not provided.
  • Physiological buffers (e.g., PBS without Ca2+/Mg2+) for downstream cell culture dilutions; avoid Mg2+/Ca2+ in storage solutions to limit nuclease activity.
• Incompatible media (general): Strong acids/bases; solutions containing RNases; prolonged storage in serum-containing media.
• Co-solvents: Organic solvents are generally unnecessary and may impair transfection; follow your transfection reagent guidance.

Comparison (general):

• Nuclease-free water: maximal flexibility; slightly less stable during long storage.
• TE (low EDTA): improved stability; ensure compatibility with transfection reagents that may be sensitive to chelators.

Item-specific solvent guidance is not specified for this product; consult the CoA/Spec Sheet and your transfection reagent manufacturer for compatibility and optimal complexation conditions.

Storage and Reconstitution

• Storage conditions (from Product Data): Store at -20°C.
• Shipping (from Product Data): Ice chest + Ice pads.
• Research use only.

Item-specific reconstitution instructions, buffer composition, concentration targets, and freeze–thaw guidance are not provided in the Product Data. Refer to the CoA/Spec Sheet for definitive directions.

General caution (not item-specific): Minimize freeze–thaw cycles by preparing single-use aliquots after initial reconstitution in nuclease-free media. Always use RNase-free consumables and aseptic technique. Verify concentration by A260 only if the appropriate extinction coefficient for the exact sequences is provided.

Structure and Identity

This product is a set of synthetic small interfering RNAs (siRNAs) pre-designed to target the human DLG4 gene (also known as PSD-95). Item-specific structural identifiers (sequence-level) are not disclosed in the Product Data.

• Product type: Pre-designed siRNA set targeting Homo sapiens DLG4
• Target gene: DLG4 (Discs Large MAGUK Scaffold Protein 4; PSD-95)
• Oligonucleotide nature: Double-stranded RNA duplexes (siRNA), typically ~21–23 nt with 3′ overhangs (literature; not item-specific)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not applicable to heterogeneous oligonucleotide mixtures; not specified for this item.
• InChIKey: Not applicable to heterogeneous oligonucleotide mixtures; not specified for this item.
• Stereochemistry: RNA ribose sugars possess defined stereochemistry (literature); item-specific configurations and modifications (if any) are not specified.
• Structural features (general/literature):
  • Anti-sense strand complementary to a selected DLG4 mRNA region; sense strand matches target sequence.
  • 5′ phosphate status and any backbone/2′-sugar modifications are not specified for this item.
  • Duplexes formulated to engage the RNA-induced silencing complex (RISC) in mammalian cells (general siRNA mechanism).

Note: Exact sequences, modification patterns, and analytic identifiers should be obtained from the item’s CoA/Spec Sheet or by contacting technical support.

Synthetic Utility

Not typically applicable. This product is a biological reagent (siRNA set) rather than a small-molecule building block or synthetic intermediate.

Guidance: For chemistry workflows, see other catalog categories. For this SKU, the relevant sections are Reaction & Applications, Biological Roles, and Reaction Conditions (transfection-related).

Target Specificity

Only information from the Product Data is included here.

• Target: DLG4 Human (PSD-95)
• Format: Pre-designed siRNA Set A (multiple siRNA duplexes targeting the human gene)

No additional specificity data (e.g., individual siRNA sequences, target exons, or off-target analyses) are provided in the Product Data. For sequence-level details or predicted target sites, consult the CoA/Spec Sheet or contact technical support with SKU D1479935.

Foire aux questions

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.